Research programme: non-nucleoside reverse transcriptase inhibitors - Bristol-Myers Squibb

Drug Profile

Research programme: non-nucleoside reverse transcriptase inhibitors - Bristol-Myers Squibb

Alternative Names: DPC-A78277; NNRTIs research programme - Bristol-Myers Squibb; Research programme: NNRTIs - Bristol-Myers Squibb

Latest Information Update: 26 Sep 2005

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 26 Sep 2005 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
  • 22 Sep 2005 Data presented at the 230th American Chemistry Society National Meeting (230th-ACS-2005) have been added to the Viral infections antimicrobial section
  • 07 Jun 2001 Preclinical trials in HIV infections treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top